WealthShield Partners’s TG Therapeutics TGTX Stock Holding History

WealthShield Partners’s Portfolio TGTX Stock Details TGTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$316K	Sell	5,750 -300	-5%	-$12.3K	0.05%	190
2026 Q1	$201K	Buy	+6,050	New	+$180K	0.02%	347
2025 Q4	–	Sell	-6,050	Closed	-$219K	–	593
2025 Q3	$219K	Hold	6,050	–	–	0.02%	320
2025 Q2	$218K	Hold	6,050	–	–	0.03%	312
2025 Q1	$239K	Buy	+6,050	New	+$204K	0.03%	293
2021 Q2	–	Sell	-4,500	Closed	-$217K	–	1122
2021 Q1	$217K	Hold	4,500	–	–	0.04%	246
2020 Q4	$234K	Buy	+4,500	New	+$152K	0.04%	263

Other funds holding TGTX

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return

SCM

Soleus Capital Management Greenwich, Connecticut $2.9B AUM 169.69% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

ClearBridge Investments New York $121B AUM 27.52% 1-Year Est. Return

CAM

Congress Asset Management Boston, Massachusetts $16.3B AUM 42.69% 1-Year Est. Return

WealthShield Partners's TGTX Position: Q2 2026 in Review

WealthShield Partners reduced its TG Therapeutics (TGTX) stake by 5% in Q2 2026, selling an estimated $12.3K and leaving 5,750 shares worth $316K. The position accounts for 0.05% of the portfolio, ranked #190.

WealthShield Partners first reported a position in TGTX in Q4 2020 and has held it in 7 quarters since. 430 funds tracked by Wall St. Rank hold TGTX as of Q2 2026.

WealthShield Partners held 5,750 shares of TG Therapeutics worth $316K as of Q2 2026.
WealthShield Partners sold 300 TG Therapeutics shares in Q2 2026, an estimated $12.3K.
TG Therapeutics made up 0.05% of WealthShield Partners's portfolio in Q2 2026, its #190 holding.
WealthShield Partners first reported a position in TG Therapeutics in Q4 2020 and has held it in 7 quarters since.
430 funds tracked by Wall St. Rank held TG Therapeutics as of Q2 2026.

Based on WealthShield Partners's 13F filing for Q2 2026, filed 12 Aug 2026.